drugset / Trial / NCT04486391
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the efficacy of tislelizumab in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Progression-free Survival (PFS) as assessed by investigator
Timeline
- Start
- 2020-12-14
- Primary completion
- 2025-10-13
- Completion
- 2025-10-13
Outcome
Outcome not reported
Stopped (Business): “Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Methylprednisolone | Other / unclassified | — | — |
| Subject | Mitoxantrone | Small molecule | — | — |
| Subject | Prednisone | Other / unclassified | — | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Vinorelbine | Small molecule | — | — |